Analysis Tools
cardiovascular system
| N |
• mice exhibit normal heart weight and cardiac function
|
|
Allele Symbol Allele Name Allele ID |
Atp2a2tm1.1Iemr targeted mutation 1.1, Ole Sejersted MGI:4415164 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal heart weight and cardiac function
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• although alive at E10.5, embryos die by E11.5
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• tamoxifen-treated mice do not exhibit myocardial disarray or necrosis
|
|
• 4 and 7 weeks after tamoxifen treatment, left atrial diameter is increased compared to in Atp2a2tm1.1Iemr homozygotes
|
|
• after tamoxifen treatment
|
|
• after tamoxifen treatment
|
|
• tamoxifen-treated mice exhibit an increase in the time constant of isovolumetric pressure decay compared with Atp2a2tm1.1Iemr homozygotes
• 7 weeks after tamoxifen treatment, mice exhibit diastolic dysfunction compared with Atp2a2tm1.1Iemr homozygotes
|
|
• 4 and 7 weeks after tamoxifen treatment
|
|
• 4 weeks after tamoxifen treatment, mice exhibit reduced contractile function compared with Atp2a2tm1.1Iemr homozygotes as determined by Doppler imaging
• at low stimulation frequency, cardiomyocytes from tamoxifen-treated mice exhibit reduced contraction magnitude compared with similarly treated cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• 7 weeks after tamoxifen treatment, fractional shortening is reduced compared to in Atp2a2tm1.1Iemr homozygotes
• 4 and 7 weeks after tamoxifen treatment, end-diastolic pressure compared to in Atp2a2tm1.1Iemr homozygotes
|
|
• 4 and 7 weeks after tamoxifen treatment, mice exhibit reduced maximum positive and minimum derivatives of the left ventricular pressure compared with Atp2a2tm1.1Iemr homozygotes
|
|
• 4 and 7 weeks after tamoxifen treatment, anesthetized mice exhibit decreased heart rate compared with Atp2a2tm1.1Iemr homozygotes
|
|
• cardiomyocytes from tamoxifen-treated mice exhibit reduced magnitude of calcium ion transients and prolonged time to half decay of calcium ion transients compared with similarly treated cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• when stimulated at a 6 Hz frequency, cardiomyocytes from tamoxifen-treated mice exhibit shorter diastolic sarcomere length and a greater increase in the contractile response per unit during systole compared with similarly treated cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• during the slow decline of caffeine transients in the presence of nickel ions, cardiomyocytes from tamoxifen-treated mice exhibit shorter sarcomere length compared with similarly treated cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• 4 weeks after tamoxifen treatment, cardiomyocytes exhibit reduced sarcoplasmic reticulum calcium ion content compared with cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• 7 weeks after treatment with tamoxifen, mice exhibit reduced maximal rate of cardiomyocyte relaxation compared with Atp2a2tm1.1Iemr homozygotes
|
|
• 7 weeks after tamoxifen treatment
|
|
• in tamoxifen-treated mice at 4 and 7 weeks
|
|
• 4 weeks after tamoxifen treatment, mice exhibit reduced contractile function compared with Atp2a2tm1.1Iemr homozygotes as determined by Doppler imaging
• at low stimulation frequency, cardiomyocytes from tamoxifen-treated mice exhibit reduced contraction magnitude compared with similarly treated cardiomyocytes from Atp2a2tm1.1Iemr homozygotes
• 7 weeks after tamoxifen treatment, fractional shortening is reduced compared to in Atp2a2tm1.1Iemr homozygotes
• 4 and 7 weeks after tamoxifen treatment, end-diastolic pressure compared to in Atp2a2tm1.1Iemr homozygotes
|
|
• after tamoxifen treatment
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||